WealthCollab’s Acadia Pharmaceuticals ACAD Stock Holding History

WealthCollab’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$112	Buy	+5	New	+$119	﹤0.01%	967
2025 Q2	–	Sell	-384	Closed	-$6.38K	–	949
2025 Q1	$6.38K	Hold	384	–	–	﹤0.01%	563
2024 Q4	$7.05K	Hold	384	–	–	﹤0.01%	521
2024 Q3	$5.91K	Buy	+384	New	+$6.41K	﹤0.01%	574
2024 Q2	–	Sell	-93	Closed	-$1.72K	–	861
2024 Q1	$1.72K	Hold	93	–	–	﹤0.01%	770
2023 Q4	$2.91K	Buy	+93	New	+$2.22K	﹤0.01%	681

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

WealthCollab's ACAD Position: Q1 2026 in Review

WealthCollab opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 5 shares worth $112. The stake represents ﹤0.01% of the portfolio and ranks #967 among its holdings. This is a return to the name: WealthCollab previously reported a position in ACAD as recently as Q1 2025.

WealthCollab first reported a position in ACAD in Q4 2023 and has held it in 6 quarters since. The position peaked at $7.05K in Q4 2024. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

WealthCollab held 5 shares of Acadia Pharmaceuticals worth $112 as of Q1 2026.
Acadia Pharmaceuticals was a new WealthCollab position in Q1 2026.
Acadia Pharmaceuticals made up ﹤0.01% of WealthCollab's portfolio in Q1 2026, its #967 holding.
WealthCollab first reported a position in Acadia Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
WealthCollab's Acadia Pharmaceuticals position peaked at $7.05K in Q4 2024.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on WealthCollab's 13F filing for Q1 2026, filed 13 May 2026.